Tourette Syndrome Market
Tourette Syndrome Market Size, Share & Industry Analysis, By Drug Class (Antipsychotics, Alpha-2 Agonists, VMAT2 Inhibitors, Others), By distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), By Route of Administration (Oral, Injectable), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa): Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
“The global Tourette syndrome market is expected to develop at a 5.2% CAGR from 2024 to 2031. The market size is estimated to reach XX in 2024 and YY in 2031.”
North America dominates the market, accounting for around YY% of total worldwide market share. Key metrics include rising diagnostic rates, increased knowledge of Tourette syndrome, and advances in treatment choices.
The Tourette syndrome market is steadily growing, owing to improved diagnostic procedures, rising condition prevalence, and the development of novel therapy options. The complexities of Tourette syndrome and its influence on quality of life continue to drive research and development efforts in this area.
Market Dynamics:
Market Trend: Emergence of Targeted Therapies and Personalized Medicine Approaches
The Tourette syndrome market is rapidly shifting towards focused medicines and personalized medicine techniques. Advances in understanding the neurological basis of Tourette syndrome, as well as appreciation of its heterogeneity, are driving this movement. Precision medicine tactics seek to tailor therapies to individual patient characteristics, such as genetic profiles and unique symptom presentations.
Recent clinical trials have yielded encouraging findings for targeted therapy in Tourette syndrome. A phase II study of 100 patients found that a new VMAT2 inhibitor created specifically for Tourette syndrome reduced tic severity by 40% compared to placebo, with little adverse effects. Industry experts believe that by 2026, more than 30% of Tourette syndrome patients will receive some type of personalized treatment, possibly altering the management of this difficult illness.
Market driver: Increasing prevalence and diagnosis rates of Tourette syndrome
Tourette syndrome is becoming more prevalent, and diagnostic rates are improving, which is driving market expansion. Tourette syndrome is one of the most prevalent neurodevelopmental disorders in children, with symptoms beginning in early childhood.
According to the Centres for Disease Control and Prevention (CDC), Tourette syndrome affects roughly one out of every 160 children (0.6%) aged 5 to 17 in the United States. The true prevalence is probably higher due to underdiagnosis. Tourette syndrome is now more commonly recognised and diagnosed due to improved awareness among healthcare practitioners and the general public. A recent epidemiological study found a 15% increase in diagnosis rates over the last five years, especially in urban regions with access to specialized neurological treatment. This expanding patient population is pushing the need for effective treatment alternatives and supportive interventions.
Market Restraint: Limited Efficacy of Current Treatments and Side Effect Concerns
While the Tourette syndrome market is growing, considerable obstacles exist due to the limited efficacy of current treatments and concerns about side effects, particularly in long-term use. Tourettes's complicated nature, with its many symptoms and frequent comorbidities, makes it difficult to design universally effective treatments.
A thorough evaluation of current Tourette syndrome treatments indicated that only YY% of individuals receive acceptable symptom management with current drugs. Furthermore, several regularly used medications, like antipsychotics, can have serious adverse effects, such as weight gain, metabolic disruption, and mobility difficulties. A survey of Tourette syndrome patients and carers found that 40% had stopped or changed drugs due to adverse effects or ineffectiveness. These concerns have the potential to limit market growth and impair patient adherence to treatment regimens, emphasizing the critical need for more effective and tolerable therapeutic options.
Segment Overview:
The antipsychotics segment dominates the Tourette syndrome market, accounting for over YY% of the market share.
Antipsychotic medicines, particularly atypical antipsychotics, have emerged as the dominant element in Tourette syndrome treatment due to their proven efficacy in reducing tic severity. This segment's dominance is due to the lengthy history of antipsychotic use in Tourette syndrome, as well as their capacity to treat both tics and prevalent comorbid conditions, including ADHD and OCD.
Market data demonstrates the antipsychotics segment's strength. According to a survey of 250 neurologists and psychiatrists, 70% use antipsychotics as the first line of treatment for moderate to severe Tourette syndrome. The market is predicted to maintain its lead until 2031, with a projected CAGR of 4.8%, owing to the release of newer antipsychotics with improved side effect profiles and ongoing research into optimizing Tourette syndrome dose regimens.
The VMAT2 inhibitors section has the fastest-growing market share because of the recent approval of valbenazine for Tourette syndrome and ongoing clinical trials of related drugs. According to industry reports, VMAT2 inhibitors have demonstrated promising results in lowering tic severity with potentially fewer metabolic side effects than standard antipsychotics, resulting in higher acceptance rates among physicians and patients alike.
Regional Outlook:
North America leads the global Tourette syndrome market, with a market share of approximately YY%.
North America's dominance in the Tourette syndrome market is due to factors such as high awareness, modern healthcare infrastructure, and the presence of important industry players and research institutions. The United States has been at the forefront of Tourette Syndrome research and clinical trials.
According to the Tourette Association of America, Tourette syndrome affects around one in every 100 school-aged children in the United States. The region's considerable emphasis on neurodevelopmental problems is seen in the substantial funding for Tourette syndrome research. For example, the National Institute of Neurological Disorders and Stroke (NINDS) has allocated more than $20 million to Tourette syndrome research in 2020 alone. This vibrant research environment, combined with favourable reimbursement regulations for neurological treatments, is driving market expansion in the region.
Europe follows closely after North America, accounting for approximately YY% of the market share. The regional market places a heavy emphasis on patient support and advocacy, with organisations such as Tourettes Action in the United Kingdom playing an important role in increasing awareness and promoting research. Countries such as Germany, France, and the United Kingdom are pioneering novel medicines and large-scale clinical trials for Tourette syndrome.
The Asia-Pacific region is emerging as a rapidly increasing market for Tourette syndrome therapies, with a projected CAGR of 6.5% by 2031. Countries such as China, Japan, and South Korea are generating significant growth by improving diagnosis rates, increasing healthcare spending, and raising awareness of neurodevelopmental diseases. For example, recent epidemiological studies in China have found Tourette syndrome prevalence rates comparable to those in Western countries, underscoring the disorder's growing attention and the need for effective therapies in the country.
Competitive Intelligence:
Established pharmaceutical businesses and specialised neurology-focused firms make up the Tourette syndrome market. To increase their market positions, key players are focussing on creating novel medicinal methods, expanding their clinical trial pipelines, and forming strategic collaborations.
Leading market players, including Teva Pharmaceutical Industries Ltd. and Otsuka Pharmaceutical Co., Ltd., have established strong positions with approved Tourette syndrome. medications. Teva's AUSTEDO (deutetrabenazine) has grown significantly in market share since its clearance for Tourette syndrome in paediatric children, with a 25% year-over-year growth in sales for movement disorder indications in 2023.
Emerging players are making tremendous progress in developing tailored therapeutics for Tourette syndrome. For example, Neurocrine Biosciences, Inc. has progressed its VMAT2 inhibitor, valbenazine, to late-stage clinical trials for Tourette syndrome, with positive phase III data expected in 2023. The company's focus on movement disorders, combined with its expertise in VMAT2 inhibition, has positioned it as a potential leader in the next generation of Tourette syndrome medicines.
The market has also seen an increase in joint efforts and license agreements. In 2023, over ten important partnerships and license agreements were announced in the Tourette syndrome arena, with the goal of integrating knowledge in areas such as neurotransmitter regulation, drug delivery technology, and paediatric formulations to produce more effective treatment techniques.
Analyst Opinion:
The Tourette syndrome market is poised for tremendous growth in the next few years, driven by a better knowledge of the disorder's pathophysiology and a pressing need for more effective, focused treatments. We believe that the use of genetic and neuroimaging biomarkers in treatment selection will become increasingly essential in Tourette syndrome care, potentially leading to better patient outcomes and more personalized therapeutic methods.
The emergence of newer pharmacological targets, such as histamine H3 receptor antagonists and cannabinoid modulators, opens up new possibilities for Tourette syndrome treatment. While current research is in its early phases, these novel techniques may provide choices for patients who do not respond well to established medicines.
Furthermore, we anticipate a rising emphasis on creating medicines that address both tics and frequent Tourette syndrome comorbidities, including ADHD and OCD. Combination therapy or multi-target drugs that can treat various components of the illness at the same time have the potential to greatly improve Tourette syndrome patients' quality of life and treatment compliance.
Major Players:
-
Teva Pharmaceutical Industries Ltd.
-
Otsuka Pharmaceutical Co., Ltd.
-
Neurocrine Biosciences, Inc.
-
AstraZeneca plc
-
Emalex Biosciences, Inc.
-
Psyadon Pharmaceuticals, Inc.
-
Therapix Biosciences Ltd.
-
Bausch Health Companies, Inc.
-
Sun Pharmaceutical Industries Ltd.
-
Luye Pharma Group Ltd.
Key Developments:
-
In September 2023, Neurocrine Biosciences, Inc. reported encouraging top-line results from a phase III trial of valbenazine in paediatric Tourette syndrome patients, revealing a substantial reduction in tic severity compared to placebo.
-
April 2024: The FDA granted Emalex Biosciences, Inc. Fast Track designation for its new D1 receptor antagonist in development for the treatment of Tourette syndrome, expediting the clinical development process.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. Teva Pharmaceutical Industries Ltd.
5.2. Otsuka Pharmaceutical Co., Ltd.
5.3. Neurocrine Biosciences, Inc.
5.4. AstraZeneca plc
5.5. Emalex Biosciences, Inc.
5.6. Psyadon Pharmaceuticals, Inc.
5.7. Therapix Biosciences Ltd.
5.8. Bausch Health Companies Inc.
5.9. Sun Pharmaceutical Industries Ltd.
5.10. Luye Pharma Group Ltd. (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Emergence of Targeted Therapies and Personalised Medicine Approaches
6.1.2. Integration of digital health technologies in Tourette syndrome management
6.1.3. Growing focus on combination therapies addressing comorbidities
6.2. Market Drivers
6.2.1. Increasing prevalence and diagnosis rates of Tourette syndrome
6.2.2. Advancements in neuroimaging and genetic research
6.2.3. Rising awareness and reduced stigma surrounding Tourette syndrome
6.3. Market Restraints
6.3.1. Limited Efficacy of Current Treatments and Side Effect Concerns
6.3.2. Challenges in clinical trial design for Tourette syndrome
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DRUG CLASS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Antipsychotics
7.1.1. Typical antipsychotics
7.1.2. Atypical antipsychotics
7.2. Alpha-2 agonists
7.2.1. Clonidine
7.2.2. Guanfacine
7.3. VMAT2 Inhibitors
7.3.1. Deutetrabenazine
7.3.2. Valbenazine
7.4. Others
7.4.1. Topiramate
7.4.2. Cannabinoids
8. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH)--2020-2031)
8.1. Hospital Pharmacies
8.1.1. Inpatient pharmacies
8.1.2. Outpatient pharmacies
8.2. Retail Pharmacies
8.2.1. Chain pharmacies
8.2.2. Independent pharmacies
8.3. Online pharmacies
8.3.1. E-commerce platforms
8.3.2. Direct-to-patient services
9. BY ROUTE OF ADMINISTRATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Oral
9.1.1. Tablets
9.1.2. Capsules
9.2. Injectable
9.2.1. Intramuscular injections
9.2.2. Subcutaneous injections
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (2020-2031)
By Drug Class:
-
Antipsychotics
-
Alpha-2 Agonists
-
VMAT2 Inhibitors
-
Others
By Distribution Channel:
-
Hospital Pharmacies
-
Retail pharmacies
-
Online pharmacies
By Route of Administration:
-
Oral
-
Injectable
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511